<DOC>
	<DOCNO>NCT00812773</DOCNO>
	<brief_summary>This study evaluate safety effect repeat oral dos GSK2190915 lung function mild asthmatic use number clinical biological marker efficacy .</brief_summary>
	<brief_title>Study Evaluate GSK2190915 Subjects With Mild Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Body mass index within range 18.535.0 kilograms/metre2 ( kg/m2 ) Female subject must non childbearing potential include premenopausal female document ( medical report verification ) hysterectomy double oophrectomy postmenopausal define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) 6 week postsurgical bilateral oophorectomy without hysterectomy . Male subject must agree use one contraception method list protocol . This criterion must follow time first dose study medication 5 terminal halflives postlast dose . Documented history bronchial asthma , first diagnose least 6 month prior screen visit currently treat intermittent shortacting beta agonist therapy inhalation . Prebronchodilator FEV1 &gt; 70 % predict screening . Subjects current nonsmoker use tobacco product 6month period precede screen visit pack history &lt; = 10 pack year . [ number pack year = ( number cigarette per day/20 ) x number year smoke ] Demonstration positive wheal flare reaction ( &gt; = 3 mm relative negative control ) least one allergen battery allergen ( include house dust mite , grass pollen cat hair ) skin prick test screening , within 12 month study start . Methacholine challenge PC20 &lt; 8 mg/mL screen previous ( last 6 month ) AMP , histamine methacholine challenge confirm diagnosis asthma Screening allergen challenge demonstrate subject experience early asthmatic response . The early asthmatic response must include fall FEV1 &gt; = 20 % post saline value , least one occasion , 5 30 minute final concentration allergen . Data obtain screen LPA111834 may use criterion . Signed date write informed consent obtain subject The subject able understand comply protocol requirement , instruction protocolstated restriction . Past present disease , judge investigator medical monitor , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , gastrointestinal disease , hepatic disease , renal disease , haematological disease , neurological disease , endocrine disease pulmonary disease Clinically significant abnormality safety laboratory analysis screening . Subject known history hypertension hypertensive screening . Hypertension screen define persistent systolic BP &gt; 150 mmHg diastolic BP &gt; 90mmHg . Respiratory tract infection and/or exacerbation asthma within 4 week prior first dose study medication History lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnoea , respiratory arrest and/or hypoxic seizures Symptomatic hay fever screening predict symptomatic hay fever time study Administration oral injectable steroid within 5 week screen intranasal and/or inhale steroid within 4 week screen visit . Unable abstain medication include nonsteroidal antiinflammatory drug ( NSAIDs ) , antidepressant drug , antihistamine antiasthma , antirhinitis hay fever medication , short act inhaled betaagonists paracetamol ( 4 g per day ) treatment minor ailment eg headache 14 day screen followup visit . Unable abstain short act beta agonist within 8 hour prior allergen challenge , dose study drug lung function assessment . If , 2 concurrent administration saline allergen challenge screen subject still fall FEV1 great 10 % . The subject participate study new molecular entity previous 3 month participate 4 clinical study previous 12 month prior first dose day . History unable tolerate complete allergen challenge test . Subject undergoing allergen desensitisation therapy . There risk noncompliance study procedure . History blood donation ( 500 mL ) within 3 month start clinical study . The subject regularly drink 28 unit alcohol week male , 21 unit per week female . One unit alcohol define medium ( 125 ml ) glass wine , half pint ( 250 ml ) beer one measure ( 25 ml ) spirit . The subject screening QTc value &gt; 450msec , PR interval outside range 120 220msec ECG suitable QT measurement ( e.g . poorly define termination Twave ) . The subject test positive hepatitis C antibody hepatitis B surface antigen . The subject test positive HIV antibody . The subject positive prestudy urine cotinine/ breath carbon monoxide test urine drug urine breath alcohol screen . A minimum list drug screen include Amphetamines , Barbituates , Cocaine , Opiates , Cannabinoids Benzodiazepines .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GSK2190915</keyword>
	<keyword>Repeat</keyword>
	<keyword>Oral</keyword>
	<keyword>Dose</keyword>
	<keyword>Challenge</keyword>
	<keyword>Asthma</keyword>
	<keyword>Allergen</keyword>
</DOC>